Wire · opportunities
'Bespoke' mRNA vaccine significantly reduces risk of melanoma recurrence or death ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 24 October 2026 · Fusion42 review
A personalised mRNA melanoma vaccine, intismeran, combined with pembrolizumab reduced melanoma recurrence or death risk by 42% in a phase III trial involving 1,137 patients worldwide. This bespoke vaccine targets up to 34 unique gene mutations per patient, representing a major advancement in personalised cancer immunotherapy.
This Wire brief sits within Fusion42's coverage of Biotech, and 7 sources have reported it between 12 Oct 2026 and 24 Oct 2026.
◆ ◆ The Wire takeaway
Cancer biotech founders can now focus on personalised vaccines targeting multiple mutations, not just single genes. Your chance is to build platforms that speed development and scale for such bespoke therapies.
◆ Coverage
7 sources · first reported 12 Oct 2026 · latest 24 Oct 2026
◆ Related on Wire
◆ Topics